with Vertex (VX22-864-108)
About the Vertex 864-108 Trial
The Vertex 864-108 Trial is exploring an investigational treatment to see how safe it is, and how well it works for people living with alpha-1 antitrypsin deficiency (AATD) who have the PiZZ genotype.
Who can join the Vertex clinical research study?
You may be able to join the VX22-864-108 Trial if you:
- Are aged 18–70
- Have been diagnosed with AATD
- Have the PiZZ genotype (if you do not know, this can be confirmed by the study team by performing a DNA test)
Please note this is not a full list of criteria.
If you are interested in taking part, you will need to answer some additional health-related questions and take part in some screening assessments to see if you meet the requirements to join the AATD clinical research study.
If you’d like to find out more or see if you can take part in the study, please complete the VX22-864-108 Inquiry Form below:
